J&J/Curis
This article was originally published in The Gray Sheet
Executive Summary
Bone morphogenic protein technology license to Johnson & Johnson/Ortho Biotech Products includes a $3.5 mil. up-front payment to Curis, plus milestones and royalties. The pact encompasses BMP compounds to be further developed as therapeutics for systemic complications of chronic kidney disease; the deal excludes musculoskeletal repair. Curis will receive $30 mil. upon FDA approval of a kidney disease product...
You may also be interested in...
Ortho Biotech, Curis Aim For BMP-7 To Prevent Need For Kidney Dialysis
Johnson & Johnson's Ortho Biotech unit plans to file an investigational new drug application in mid-2004 for use of recombinant bone morphogenic protein-7 to treat kidney dialysis patients
Boston Scientific Leads The Charge For Stem Cell Alliances With Osiris Stake
Boston Scientific's investment in stem cell therapy developer Osiris Therapeutics may signal a wave of device/biotech collaborations related to delivery techniques for stem cell treatments
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.